Links between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges: Mechanistic and Therapeutic Challenges

Tissue fibrosis may occur for unknown causes or be the consequence of many pathological conditions including chronic inflammatory or infectious diseases, autoimmune disorders, graft rejection, or malignancy. On the other hand, malignant tumors have been identified in fibrotic tissues decades ago, an...

Full description

Bibliographic Details
Format: eBook
Language:English
Published: MDPI - Multidisciplinary Digital Publishing Institute 2019
Subjects:
DHA
EMT
HBV
HCV
n/a
TAZ
Wnt
YAP
Online Access:Open Access: DOAB: description of the publication
Open Access: DOAB, download the publication
LEADER 05385namaa2201405uu 4500
001 doab51774
003 oapen
005 20210211
006 m o d
007 cr|mn|---annan
008 210211s2019 xx |||||o ||| 0|eng d
020 |a 9783039217069 
020 |a 9783039217076 
020 |a books978-3-03921-707-6 
024 7 |a 10.3390/books978-3-03921-707-6  |2 doi 
040 |a oapen  |c oapen 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
720 1 |a Gabazza, Esteban C.  |4 aut 
245 0 0 |a Links between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges: Mechanistic and Therapeutic Challenges 
260 |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2019 
300 |a 1 online resource (348 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |f Unrestricted online access  |2 star 
520 |a Tissue fibrosis may occur for unknown causes or be the consequence of many pathological conditions including chronic inflammatory or infectious diseases, autoimmune disorders, graft rejection, or malignancy. On the other hand, malignant tumors have been identified in fibrotic tissues decades ago, and now accumulating evidence suggests that fibrotic lesions enhance the risk of cancer in several organs such as liver, lungs, and breast. Disruption of an organ parenchymal cells and of its normal structural scaffold during tissue fibrogenesis appears to induce loss of cell polarity, promoting uncontrolled cell proliferation that may eventually lead to cancer development. Many cellular and molecular abnormalities including aberrant expression of microRNAs, genetic and epigenetic alterations, evasion or delayed apoptosis, unregulated intracellular signal pathways, and dysregulation or defective intercellular communications have been proposed to explain this link between fibrogenesis and carcinogenesis. However, the precise mechanisms of this fibrosis-to-cancer transition remain unclear. This book presents a collection of reviews and original articles summarizing recent advances in understanding the molecular mechanisms of cancer development in fibrotic organs. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by-nc-nd/4.0/  |2 cc  |u https://creativecommons.org/licenses/by-nc-nd/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a acute lung injury 
653 |a anaplastic lymphoma kinase 
653 |a angiogenesis 
653 |a antitumor efficacy 
653 |a apoptosis 
653 |a bleomycin 
653 |a breast cancer 
653 |a butylidenephthalide 
653 |a cancer 
653 |a cancer-associated fibroblasts 
653 |a cancer-associated fibroblasts (CAFs) 
653 |a carcinogenesis 
653 |a cirrhosis 
653 |a clinical symptoms 
653 |a common pathways 
653 |a crizotinib 
653 |a cystic formation 
653 |a cytokine 
653 |a cytokines 
653 |a DHA 
653 |a diagnosis 
653 |a EMT 
653 |a Erk1/2 
653 |a extracellular matrix 
653 |a fibrosis 
653 |a genetic instability 
653 |a GPR120 
653 |a GPR40 
653 |a growth factor 
653 |a HBV 
653 |a HCV 
653 |a hepatic stellate cells 
653 |a hepatic stellate cells (HSCs) 
653 |a hepatocellular carcinoma 
653 |a hepatocellular carcinoma (HCC) 
653 |a hepatocytes 
653 |a heterogeneity 
653 |a Hippo pathway 
653 |a idiopathic pulmonary fibrosis 
653 |a idiopathic pulmonary fibrosis (IPF) 
653 |a immunohistochemistry 
653 |a inflammation 
653 |a interstitial fluid pressure 
653 |a leiomyoma 
653 |a leiomyosarcoma 
653 |a lipopolysaccharide 
653 |a lncRNA 
653 |a lung cancer 
653 |a lung cancer (LC) 
653 |a marker 
653 |a mechanotransduction 
653 |a metabolic reprogramming 
653 |a metastasis 
653 |a miRNA 
653 |a myometrium 
653 |a n/a 
653 |a nanoparticles 
653 |a non-alcoholic steatohepatitis 
653 |a non-small cell lung cancer (NSCLC) 
653 |a omega-3 fatty acid 
653 |a pathogenesis 
653 |a pathology 
653 |a pathophysiology 
653 |a protein S 
653 |a pulmonary fibrosis 
653 |a reactive oxygen species 
653 |a regeneration 
653 |a renal injury 
653 |a signal pathway 
653 |a SMAD 
653 |a smooth muscle tumor of uncertain malignant potential 
653 |a SOX2 
653 |a SREBP-1 
653 |a targeted therapy 
653 |a TAZ 
653 |a TGF-? 
653 |a therapy 
653 |a transforming growth factor-? 
653 |a tumor 
653 |a tumor microenvironment 
653 |a tumor necrosis factor ? 
653 |a tumor stiffness 
653 |a type I collagen 
653 |a uterine fibroid 
653 |a Wnt 
653 |a YAP 
793 0 |a DOAB Library. 
856 4 0 |u https://directory.doabooks.org/handle/20.500.12854/51774  |7 0  |z Open Access: DOAB: description of the publication 
856 4 0 |u https://mdpi.com/books/pdfview/book/1794  |7 0  |z Open Access: DOAB, download the publication